4th Annual Clinical Site Partnerships in Central & Eastern Europe, to be held in Budapest, Hungary

7th-8th Septermber 2009, Budapest, Hungary.
Central & Eastern Europe continues be one of the most attractive regions globally for running clinical trials. With it's substantial pool of patients, centralized healthcare system and highly motivated investigators it still offers time, cost and quality advantages over other territories.

This event will build upon our previous meetings by examining in detail the current clinical landscape impacting clinical trials in the CEE & CIS regiondealing with longstanding regulatory obstacles, site selection and performance hurdles, approaches to ensure the quality and integrity of data and improving understanding of clinical trials amongst the region's population. Particular attention will also be given to the continuing barriers to improvements in EU member states as well as Russia, Ukraine and the Balkan regions via focused conference sessions.

NextLevel Pharma's "Clinical Site Partnerships in Central & Eastern Europe" event is the only meeting which provides the opportunity to participate in 1 on 1 partnering sessions enabling trial sponsor companies, CROs, clinical solution providers, and sites themselves to meet with one another to discuss potential partnerships.

Why attend:

  • Learn how CEE can consolidate its position as a highly productive region for clinical research.
  • Hear fresh perspectives from Ministries of Health, ethics committees, clinical research associations, patient organisations and sites as well as sponsor companies on how to improve the region's clinical research infrastructure.
  • Gain vital local knowledge and improve relationships by hearing from sites directly via presentations and partnering meetings.
  • Develop your approach to train, motivate and support clinical teams in these specific regions.
  • Case study presentations from experts with focus also given to Russia, Ukraine, Turkey and the Balkans.
  • Learn and implement the most efficient partnership model in CEE to maximise the performance of your clinical partners.
  • Partner with the leading clinical solution providers operating in CEE/CIS in our exclusive 1-on-1 partnering sessions.
  • Network and build the contacts & relationships you need at NextLevel Pharma's very popular & entertaining networking dinner.

Who will benefit:

  • Pharmaceutical & Biotechnology Organisations: Global / European / Regional / Country Heads of Clinical Operations, Clinical Development, Outsourcing, Contract Management, Risk Management, R&D Sourcing, Business Development. Project Managers, Study Managers, and Senior CRAs,
  • CROs & Clinical Solution Providers: CEOs, Business Development Directors, Product Managers, Marketing Managers and Country Managers from the region.
  • Clinical Sites: Principal Investigators, Co-Investigators, Study Coordinators, Study Nurses and others involved in clinical research.

For further information and registration, please visit:
https://www.nextlevelpharma.com/events/view/4th_annual_clinical_site_partnerships_in_central_eastern_europe

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...